Evrenzo Astellas Pharma Europe B.V. · Authorised · authorised 18 Aug 2021 · ATC B03XA05
Therapeutic indication (EMA)
Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
Active substance
Roxadustat
- SFDA 5
- EMA 1
- NHS prices 4
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Evrenzo | 50 mg | Film-coated tablet · Oral use | 12 Blister | SAR 715.20 | NCE · Prescription | ASTELLAS PHARMA | Valid |
| Evrenzo | 100 mg | Film-coated tablet · Oral use | 12 Blister | SAR 1347.75 | NCE · Prescription | ASTELLAS PHARMA | Valid |
| Evrenzo | 150 mg | Film-coated tablet · Oral use | 12 Blister | SAR 2021.60 | NCE · Prescription | ASTELLAS PHARMA | Valid |
| Evrenzo | 20 mg | Film-coated tablet · Oral use | 12 Blister | SAR 290.05 | NCE · Prescription | ASTELLAS PHARMA | Valid |
| Evrenzo | 70 mg | Film-coated tablet · Oral use | 12 Blister | SAR 1015.30 | NCE · Prescription | ASTELLAS PHARMA | Valid |
Indications — CHI Daman Drug Formulary
ANEMIA IN CHRONIC KIDNEY DISEASE
EMA European Union — centrally authorised medicines
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Roxadustat 100mg tablets | £296.21 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Roxadustat 20mg tablets | £59.24 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Roxadustat 50mg tablets | £148.11 | 12 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Roxadustat 70mg tablets | £207.35 | 12 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 13 Jun 2024 PRAC signal: Thrombocytopenia
Action for MAH: update of the product information: No - EMA PRAC 13 Jan 2022 PRAC signal: Central hypothyroidism
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.